Gastroenterologists who engage in buy and bill are more likely to perform ancillary services than those who do not.
"Buy and bill" refers to the process in which a healthcare provider or practice purchases, stores and administers a therapy to a patient, then submits a reimbursement claim to a third-party payer.
This data comes from RealTime Dynamix: Ulcerative Colitis (U.S.) fourth quarter. The trends were confirmed in second-quarter and third-quarter data.
Gastroenterologists engaging in buy and bill (59 respondents):
- Two percent do not offer ancillary services.
- Thirty-one percent choose Janssen as the most supportive to their practice.
- Ninety-three percent offer infusion.
- Thirty-six percent reported an increase in Inflectra UC use over the past three months.
- Thirty-seven percent reported a decrease in Humira UC use over the past three months.
- Thirty-five percent choose AbbVie as the most supportive to their practice.
Gastroenterologists not engaging in buy and bill (25 respondents):
- Sixteen percent do not offer ancillary services.
- Twelve percent choose Janssen as the most supportive to their practice.
- Thirty-two percent offer infusion.
- Twelve percent reported an increase in Inflectra UC use over the past three months.
- Twenty-four percent reported a decrease in Humira UC use over the past three months.
- Sixty percent choose AbbVie as the most supportive to their practice.